Plain-English translation of NCT06541327 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a data collection study for adults with lymphoma that has come back or stopped responding to standard treatment. Researchers are gathering information from patients who receive cellular immunotherapy — including CAR-T cells, NK cells, and other immune-based treatments — to learn how effective these therapies are and what side effects patients experience.
Relapsed or refractory lymphoma is difficult to treat, and newer immune cell therapies offer hope, but doctors need more real-world data to understand which approaches work best for different patients and how to manage side effects safely.
You likely qualify if…
You likely don't qualify if…
If you enroll, researchers will collect your medical information at several time points: before your immune cell treatment, right before the cells are infused, on the day of infusion, and during follow-up visits for up to 2 years afterward. They will track how well the treatment works, any side effects you experience, and your overall health — but they will not change your actual treatment plan based on this study.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China
Enrollment target
~1,000 participants
Started
May 2024
Primary completion
December 2040
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Weili Zhao
Ruijin Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.